title: Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab.
abstract: Systemic AA amyloidosis is a serious complication of many chronic inflammatory disorders. Its association with Crohn's disease implies that the inflammatory burden is high enough for amyloid fibrils to form deposits in tissues. A case is presented in which this complication occurred while the patient was clinically well, with biological and endoscopic markers showing an inactive or mildly active disease under anti-tumor necrosis factor alpha therapy.
authors.affiliation: Gastroenterology Department, Instituto Portugus de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal. catarinafidalgo@inbox.com
authors.forename: Catarina
authors.initials: C
authors.lastname: Fidalgo
authors.forename: Joaquim
authors.initials: J
authors.lastname: Calado
authors.forename: Marilia
authors.initials: M
authors.lastname: Cravo
mesh_terms: D000328:Adult; D000682:Amyloid / Q000378:metabolism; D000686:Amyloidosis / Q000209:etiology* / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000682:Amyloid; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab